BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
The synthetic lethality specialist licenses in its second ADC in six months.
